{
  "docId": "019de075-5375-74ac-b63e-223f7dcbcdee",
  "docSlug": "1e5a737805b52115da5825472ef93325",
  "documentTitle": "Hillstream BioPharma | Investor Presentation Deck | 19 slides",
  "authorId": "hillstream-biopharma",
  "authorName": "Hillstream BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 19,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The diagram illustrates the binding mechanism of the antibody to the cell surface receptors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5375-74ac-b63e-223f7dcbcdee/8",
  "deckHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee",
  "deckJsonHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee.json",
  "deckAnchorHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.55,
        "x": 0.42,
        "y": 0.18
      },
      "kind": "image",
      "text": "Diagram showing antibody binding to HER2/HER2 and HER2/HER3 receptor pairs on a cell membrane.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90113bba-fb83-4738-a50a-f99e929183bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.38,
        "x": 0.04,
        "y": 0.28
      },
      "kind": "list",
      "text": "HER2 is a known validated cancer target with antibodies like Herceptin (appr. in 1998). HSB-3215: Targets novel conformational epitopes bridging Domains III & IV on HER2. Well trodden path to clinical development. Novel structure and efficacy against sub-groups of HER2 not impacted by Herceptin.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16d18e8f-f1bd-4d00-b8a0-0ba90d695e92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.22,
        "x": 0.29,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Herceptin is a registered trademark of Genentech, Inc",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0722429c-7a83-407b-8c1b-8fbcb4707c41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "HSB-3215: Anti-HER2/HER3 mAb Targeting Novel Epitopes",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "666151c6-7b26-4ec7-811e-e9e2fb82c0c3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 4,
      "beatId": "e53add27-632d-4b4f-baf0-308f53797da9",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 4-14 present the company's solution, including the lead program HSB-3215 and its technical advantages",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}